Suven Life Sciences Limited

BSE:530239 Stock Report

Market Cap: ₹21.6b

Suven Life Sciences Past Earnings Performance

Past criteria checks 0/6

Suven Life Sciences's earnings have been declining at an average annual rate of -33.6%, while the Life Sciences industry saw earnings growing at 9.8% annually. Revenues have been declining at an average rate of 81% per year.

Key information

-33.6%

Earnings growth rate

-26.7%

EPS growth rate

Life Sciences Industry Growth11.2%
Revenue growth rate-81.0%
Return on equity-38.9%
Net Margin-898.6%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Suven Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:530239 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24117-1,0511901,144
31 Dec 23120-1,0621951,158
30 Sep 23125-1,1551841,230
30 Jun 23139-1,2601901,219
31 Mar 23136-1,1831861,154
31 Dec 22153-1,1142041,019
30 Sep 22167-940208831
30 Jun 22135-991208861
31 Mar 22120-1,2202101,064
31 Dec 2198-1,2281941,089
30 Sep 2169-1,1351891,015
30 Jun 21147-1,009195990
31 Mar 21141-722185710
31 Dec 20209-761188809
30 Sep 20221-745176819
30 Jun 20142-787164777
31 Mar 20147-9421751,032
31 Dec 193,863285191,224
30 Sep 198,5591,4667781,320
30 Jun 196,7118717521,349
31 Mar 192,860-2393961,189
31 Mar 186,2551,237656902
31 Mar 175,437872563991
31 Mar 164,998718442904
31 Dec 154,409796633616
30 Sep 154,572941613621
30 Jun 154,803942580595
31 Mar 155,2091,088390560
31 Dec 145,4101,242367451
30 Sep 145,3161,284526428
30 Jun 145,4321,491524497
31 Mar 145,1031,442511487
31 Dec 134,5421,204461475
30 Sep 133,972917431470
30 Jun 132,960526411360

Quality Earnings: 530239 is currently unprofitable.

Growing Profit Margin: 530239 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 530239 is unprofitable, and losses have increased over the past 5 years at a rate of 33.6% per year.

Accelerating Growth: Unable to compare 530239's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 530239 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (2.6%).


Return on Equity

High ROE: 530239 has a negative Return on Equity (-38.91%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.